source
- Diabetes cell-therapy firms Sernova and Seraxis announce mergerTwo diabetes-focused cell-therapy companies, Sernova and Seraxis, have agreed to merge after decades of developing treatments for the disease. The combined company aims to pool resources and exper…
- Pharvaris reports 83% drop in hereditary angioedema attacks in phase 3 trial, FDA decision pendingPharvaris announced that its oral bradykinin B2 receptor antagonist, deucrictibant, met the primary goal in a second phase 3 study. The trial, called CHAPTER-3, enrolled 85 patients with three for…